comparemela.com

Latest Breaking News On - Bymonica stonehill - Page 1 : comparemela.com

Bariatric surgery significantly reduced major adverse liver outcomes in MASH cirrhosis

At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.“Previous studies suggested excellent clinical outcomes in patients with MASH and fibrosis stages 1 to 3 with improvement in both cardiac and

Elafibranor has significant, sustained treatment benefit in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

A catered low-fat, high-fiber diet new, hopeful option to manage Crohn s disease

WASHINGTON — Patients with Crohn’s disease who ate a catered low-fat, high-fiber diet for 8 weeks experienced improvements in symptoms, inflammation and quality of life vs. those offered counseling alone, researchers reported. “We know that most patients with Crohn’s disease seek dietary counseling and ask their physicians about the foods they should consume,” Hajar

Entyvio effective in pediatric IBD, should be included in our treatment paradigm

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher. “We know that children with inflammatory bowel disease, compared to adults, can have a more severe disease phenotype that is

Noninvasive tests identify candidates for Rezdiffra, predict response in patients with MASH

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis. “We wanted to identify if we could predict response to treatment among patients treated with resmetirom,” Rohit Loomba, MD, MHSc, professor of medicine and chief of

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.